Highest-materiality recent filing
Select Medical Q1 EPS $0.35 vs $0.44; revenue +5% to $1.42B; merger on track
Revenue $1,421.5M +5.0% YoY; net income $63.8M vs $74.7M; diluted EPS $0.35 vs $0.44.
Select Medical to be acquired by consortium led by Ortenzio, Jackson, WCAS for $16.50/share
Enterprise value of $3.9B; Merger Consideration of $16.50 per share in cash.
Select Medical reports Q4 growth, 2026 outlook; Ortenzio take-private bid under review
Q4 revenue $1,396.6M (+6.4%), net income $37.7M, diluted EPS $0.16 vs loss $0.19 YoY.
Select Medical receives take-private proposal from Executive Chairman at $16-$16.20/share
Non-binding proposal to acquire all outstanding shares for $16.00-$16.20 cash per share.
Select Medical Q3 revenue up 7.2% to $1.36B, EPS $0.23; raises FY25 EPS guidance
Q3 revenue $1,363.4M (+7.2% YoY); income from cont ops $44.2M (+7%); Adj EBITDA $111.7M (+7.5%).
Select Medical names Thomas P. Mullin CEO; David Chernow becomes Vice Chairman
Mullin, 41, promoted from Co-President, effective Sept 1, 2025; Chernow (CEO since 2014) becomes Vice Chairman.
Select Medical Q2 revenue +4.5% to $1.34B, EPS $0.32, reaffirms FY2025 outlook
Revenue $1,339.6M (+4.5% YoY); net income from continuing ops $57.9M (+53.8%).
Select Medical Q1 revenue up 2.4%, EPS rises 33% but core segment weakens; guidance lowered
Revenue $1,353.2M (+2.4% YoY); net income from cont. ops $74.7M (+21.5%); EPS $0.44 (+33.3%).
Select Medical Q4 revenue +7.8% to $1.31B, adjusted EPS +50%; issues 2025 outlook
Q4 revenue $1.31B (+7.8% YoY); loss from continuing ops $10.5M vs profit $30.3M (impacted by $45.9M stock comp acceleration and $17.9M debt retirement loss).
Net proceeds used to repay existing term loans and redeem all outstanding 6.250% Senior Notes due 2026.
Select Medical completes spin-off of Concentra, distributing 104M shares worth $2.3B
104,093,503 shares of Concentra (81.7% stake) distributed to Select stockholders as of Nov 18 record date.
Final ratio: 0.806971 shares of Concentra (CON) per SEM share; based on 128,992,850 SEM shares outstanding as of Record Date Nov 18.
Select Medical Corporation plans $850M senior notes due 2032 in a private placement; notes guaranteed by certain domestic subsidiaries.
Select Medical spins off 81.7% Concentra stake via special stock distribution
Distribution of 104,093,503 Concentra shares (81.7% of CON) to SEM stockholders on Nov 25, 2024.
Select Medical Q3 revenue up 5.7% to $1.76B; net income +33.2%; dividend $0.125; FY guidance updated
Q3 revenue $1,761.2M (+5.7% YoY); net income $81.0M (+33.2%); adjusted EPS $0.50 (+8.7%).
Select Medical completes Concentra IPO of 22.5M shares at $23.50, retains ~82% stake
IPO of 22.5M shares of Concentra common stock at $23.50/share; net proceeds $499.7M.
Select Medical Q2 revenue up 5.1% to $1.76B, EPS $0.60; Concentra IPO raises $528.8M
Q2 rev $1,759.7M (+5.1% YoY), net income $94.8M (+3.2%), GAAP EPS $0.60 vs $0.61 prior.
Select Medical subsidiary issues $650M 6.875% Senior Notes due 2032
$650M aggregate principal of 6.875% senior notes due July 15, 2032, issued by Concentra Escrow Issuer Corp.
Select Medical estimates Concentra Q2 rev $477.9M, op income $83.9M
Concentra net operating revenue ~$477.9M for Q2 2024; income from operations ~$83.9M.
Select Medical's Concentra subsidiary prices $650M of 6.875% senior notes due 2032
$650M aggregate principal of 6.875% senior notes due 2032 priced by Concentra Escrow Issuer.
Revenue $1,788.8M (+7.4% YoY); net income $117.2M (+37.4%); GAAP EPS $0.75 (+33.9%).
On July 31, 2024, the Board of Directors (the “Board”) of the Company appointed David S. Chernow as a director of the Company, effective August 1, 2024, in order to fill the vacancy created by Mr. Ortenzio’s resignation.
Rocco A. Ortenzio, a director of Select Medical Holdings Corporation (the “Company”), notified the Company of his decision to resign as a director, effective August 1, 2024.
Max materiality 0.85 · Median 0.70 · Most common event earnings